SciLifeLab Fellow at Uppsala University
Yumeng Mao is supported by the SciLifeLab Fellow Programme to establish a research group on translational cancer immunology at IGP, Uppsala University. Prior to his appointment, he was a full time employee at AstraZeneca Oncology R&D Headquarters in Cambridge, UK, where he led early stage small molecule drug discovery projects. Yumeng received his doctoral and post-doctoral training at the Karolinska Institute under the mentorship of Prof Rolf Kiessling.
Activation of the human immune system through blockade against the programmed cell death protein 1 (PD-1) or its ligand PD-L1 has led to the approval of several innovative medicines for cancer patients. However, 80% of the patients fails to enjoy long-term benefits, probably due to multiple resistance mechanisms in the tumour micro-environment. My group aims to reveal the functional hierarchy and dominant pathways in myeloid cells and cancer cells, in order to reveal novel pathways that can enhance the efficacy of the PD-1/L1 blockage. We have a special focus on rare cancer types with significant unmet medical needs such as childhood neuroblastoma. To achieve this, we will develop and optimise a suite of pre-clinical assays and models using the CRISPR/Cas9-based precise genome editing approach. In a long run, we hope to build an inter-disciplinary framework to achieve data-led hypothesis generation and pathway validation for cancer immunotherapy.
Host: Mia Phillipson
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.